Lipum Q3’22 - We have liftoff
2022-11-25 11:00:00
Redeye leaves a comment on the Q3 report published by Lipum earlier this morning. A quarter marked by the historical initiation of the first clinical trial with the company’s lead candidate, SOL-116.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.